Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for HIV-Associated Lipodystrophy Syndrome

• Contribution of Dolutegravir to Obesity and Cardiovascular Disease
• Body Composition and Adipose Tissue in HIV
• Energy Expenditure of People Living With HIV/AIDS
• An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects
• Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
• Strategies of Interruption/Reinitiation of Antiretroviral Therapy in HIV-Infected Patients With Lipodystrophy
• TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy
• HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)
• Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients
• Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.
• Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients
• Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome
• Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
• Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients
• Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy
• MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)